Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Volociximab

Generic Name: Volociximab

Drug Type: Biotech

CAS Number: 558480-40-3

Unique Ingredient Identifier: 496K5Z02NW

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

Phase 1

Completed

Posted: 2008/10/31

Sponsor:

Ophthotech Corporati...

ID:NCT00782093

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Phase 2

Terminated

Posted: 2007/08/16

Sponsor:

Facet Biotech

ID:NCT00516841

A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

Phase 2

Completed

Posted: 2006/11/20

Sponsor:AbbVie (prior sponso...

ID:NCT00401570

A Study of Volociximab in Metastatic Melanoma

Phase 2

Terminated

Posted: 2006/08/29

Sponsor:Abbott

ID:NCT00369395

Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)

Phase 2

Terminated

Posted: 2005/01/05

Sponsor:Abbott

ID:NCT00100685

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy